Tenofovir disoproxil fumarate significantly decreases serum lipoprotein levels compared with entecavir nucleos(t)ide analogue therapy in chronic hepatitis B carriers

Abstract

A greater decline in TC, LDL-C and HDL was observed in CHB carriers receiving TDF compared with ETV. These data may influence anti-viral choice in CHB carriers at risk for CVD.

Letter: lipid‐lowering effect of tenofovir disoproxil fumarate in chronic hepatitis B—more evidence is needed

“…1 However, no significant difference was found in CHB patients who received ETV treatment. 1 The study is very interesting. However, several issues deserve discussion.…”

“…1 In the entire cohort, 25% of the patients were HBeAg-positive. 1 Moreover, only about 10% of the patients had detectable HBV-DNA and 19% were cirrhotic at baseline.…”

“…1 In the entire cohort, 25% of the patients were HBeAg-positive. 1 Moreover, only about 10% of the patients had detectable HBV-DNA and 19% were cirrhotic at baseline. 1 Thus, it seems that most of the patients who had received TDF or ETV did not meet the indications for anti-viral treatment of CHB as recommended by the international guidelines.…”

“…1 Moreover, only about 10% of the patients had detectable HBV-DNA and 19% were cirrhotic at baseline. 1 Thus, it seems that most of the patients who had received TDF or ETV did not meet the indications for anti-viral treatment of CHB as recommended by the international guidelines. [2][3][4] Thus, the results might be biased due to the patient selection.…”

“…1 However, the number of patients co-infected with hepatitis C virus (HCV) was not described. Epidemiologic and clinical data indicate that HCV may interact with the host lipid metabolism by several mechanisms leading to hypolipidaemia.…”